NCT03394911View on ClinicalTrials.gov

Healthy Adult Male Facial Skin Surface Lipid Pheromone p.o. to Treat Opioid Addiction

PHASE3UnknownINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

December 31, 2020

Primary Completion Date

November 30, 2021

Study Completion Date

November 30, 2021

Conditions
Opioid AddictionOpioid Abuse, Continuous UseOpioid UseOpioid-Related DisordersPaternal Pheromone DeficiencyOpioid DependenceOpioid AbuseOpioid-use DisorderOpioid IntoxicationOpioid Abuse, Episodic
Interventions
BIOLOGICAL

250mg healthy adult male facial skin surface lipid liquid pheromone

Human Pheromone provided p.o. to tox-screen verified opioid drug addict

Sponsors

Collaborators (1)

Otrimed Clinical Research
All Listed Sponsors
collaborator

Tampa General Hospital

OTHER

collaborator

Otrimed Clinical Research

OTHER

lead

Bubba Nicholson

INDUSTRY

NCT03394911 - Healthy Adult Male Facial Skin Surface Lipid Pheromone p.o. to Treat Opioid Addiction | Biotech Hunter | Biotech Hunter